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Abstract
Objective: To determine the relationship between high vaginal pro-inflammatory cytokines and cervical shortening in
women at high risk of spontaneous preterm labor and to assess the influence of cervical cerclage and vaginal progesterone
on this relationship.
Methods: This prospective longitudinal observational study assessed 112 women with at least one previous preterm
delivery between 16 and 34 weeks’ gestation. Transvaginal cervical length was measured and cervico-vaginal fluid sampled
every two weeks until 28 weeks. If the cervix shortened (,25 mm) before 24 weeks’ gestation, women (cases) were
randomly assigned to cerclage or progesterone and sampled weekly. Cytokine concentrations were measured in a subset of
cervico-vaginal fluid samples (n = 477 from 78 women) by 11-plex fluid-phase immunoassay.
Results: All 11 inflammatory cytokines investigated were detected in cervico-vaginal fluid from women at high risk of
preterm birth, irrespective of later cervical shortening. At less than 24 weeks’ gestation and prior to intervention, women
destined to develop a short cervix (n = 36) exhibited higher cervico-vaginal concentrations than controls (n = 42) of
granulocyte-macrophage colony-stimulating factor [(GM-CSF) 16.2 fold increase, confidence interval (CI) 1.8–147; p = 0.01]
and monocyte chemotactic protein-1 [(MCP-1) 4.8, CI 1.0–23.0; p = 0.05]. Other cytokines were similar between cases and
controls. Progesterone treatment did not suppress cytokine concentrations. Interleukin (IL)-6, IL-8, granulocyte colony-
stimulating factor (G-CSF), interferon (IFN)-c and tumour necrosis factor (TNF)-a concentrations were higher following
randomization to cerclage versus progesterone (p,0.05). Cerclage, but not progesterone treatment, was followed by a
significant increase in cervical length [mean 11.4 mm, CI 5.0–17.7; p,0.001].
Conclusions: Although GM-CSF and MCP-1 cervico-vaginal fluid concentrations were raised, the majority of cervico-vaginal
cytokines did not increase in association with cervical shortening. Progesterone treatment showed no significant anti-
inflammation action on cytokine concentrations. Cerclage insertion was associated with an increase in the majority of
inflammatory markers and cervical length.
Citation: Chandiramani M, Seed PT, Orsi NM, Ekbote UV, Bennett PR, et al. (2012) Limited Relationship between Cervico-Vaginal Fluid Cytokine Profiles and
Cervical Shortening in Women at High Risk of Spontaneous Preterm Birth. PLoS ONE 7(12): e52412. doi:10.1371/journal.pone.0052412
Editor: Eduard Gratacos, Hospital Clinic, University of Barcelona, Spain
Received July 2, 2012; Accepted November 13, 2012; Published December 26, 2012
Copyright:  2012 Chandiramani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Research was supported by a grant from Action Medical Research (SP4113) and the National Institute for Health Research (NIHR) Comprehensive
Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: m.chandiramani@imperial.ac.uk
Introduction
Preterm birth is a major challenge facing modern obstetrics,
with a global prevalence of 9.6% and over a million annual
neonatal deaths [1]. Spontaneous preterm labour (SPTL), which
accounts for 75% of these births, is likely to be initiated by a
variety of factors [2], thereby hindering accurate identification of
at-risk women. Current clinical management is also disparate [3–
11] and the effectiveness of interventions such as cervical cerclage
and progesterone to improve neonatal outcome remain to be
proven. This may, in part, reflect an ineffective understanding of
the cellular mechanisms involved and mis-categorization of patient
risk status resulting in inappropriate treatment.
Mounting evidence implicates involvement of inflammatory
mediators in preterm labor [12–13], although the processes
involved are unclear. Ascending infection, it is proposed, leads
to activation of inflammatory pathways, which precede cervical
shortening [14] and, because of this, inflammatory mediators,
including cytokines and chemokines, have been frequently
measured in cervico-vaginal secretions and amniotic fluid of
women delivering preterm [15–21]. In the most recent systematic
review [22], IL-6 has been shown to be strongly associated with
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SPTL in asymptomatic women, whilst cervical mucus IL-8 has
been used to determine if cerclage insertion will be beneficial [23].
Prospective longitudinal data which enable interrogation of
temporal relationships are, however, scarce and most studies rely
on a ‘snap-shot’ approach with single point sampling in the second
trimester [21,24–27]. It has been hypothesized, by us and others
[2,5], that inflammation precedes and mediates cervical shortening
and anti-inflammatory treatments (such as progesterone) reduce
further shortening as a mechanism for preventing preterm labor.
Our aim was to prospectively investigate cervico-vaginal fluid
inflammatory markers longitudinally in tandem with cervical
length and to examine the influence of cervical cerclage and
progesterone treatment. We anticipated that inflammatory
responses may be specific to individual women and that there is
a need to understand this process as the first step in directing
interventions and informing personalized healthcare.
Methods
Study Population and Design
This prospective observational study was approved by St
Thomas’ Hospital Research Ethics Committee (06/Q0704/66)
and all patients provided written informed consent. Women were
enrolled from two preterm surveillance clinics at two teaching
hospitals in London between 16 and 24 weeks’ gestation from June
2006 until November 2008. Women with at least one prior
spontaneous preterm birth between 16 and 34 weeks’ gestation
were eligible to participate. Exclusion criteria included multiple
pregnancies, previous iatrogenic preterm births and inability to
give informed consent. Recruits were initially assessed every 2
weeks by transvaginal cervical length assessment as well as cervico-
vaginal fluid and blood sampling between 16 and 28 weeks’
gestation. All women provided a cervico-vaginal fluid sample prior
to cervical length assessment at every visit.
If the cervical length shortened to less than 25 mm before 24
weeks’ gestation, women (allocated to the case group) were offered
a routine treatment (either cervical cerclage or vaginal progester-
one) as per clinical practice. However, in order to ensure equal
numbers for analysis and to explore the impact of treatments on
cervical inflammation, women were assigned equally to either
treatment using computer generated open-label randomization by
the study investigator. Samples and scans were repeated weekly
thereafter in women found to have a short cervix. Natural
progesterone CyclogestH 400 mg once daily (Actavis UK Ltd,
Devon, UK) administered vaginally was used based on current
clinical practice in light of insufficient contemporary evidence of
optimal route and dose of progesterone administration. Women
who did not develop a short cervix by 24 weeks’ gestation were
allocated to the control group. Routine screening for vaginal
organisms such as bacterial vaginosis, Trichomonas and Candida
was not included in the study protocol, but if women presented
with suggestive symptoms, a high vaginal swab was taken and
women were treated based on antimicrobial sensitivities.
Technique of Cervical Length Assessment
Cervical length was assessed in accordance with standardised
guidelines [28]; in summary, a sagittal view of the cervix was
obtained with the long axis view of the echogenic endocervical
mucosa along the length of the canal, allowing identification of
both the internal and external os. Without causing undue pressure
on the cervix with the probe, the linear distance between the
external and internal os was recorded 3 times in millimeters over a
minimum of 3 minutes using optimal magnification and zoom
settings and the shortest one recorded. Transfundal pressure was
exerted for 15 seconds and subsequent demonstration of a funnel
was noted. The total closed length in all women was measured and
if a cerclage was present, the closed length cranial to the cerclage
were also recorded. Approximately 90% of the measurements
were undertaken by one investigator (MC), while a second
investigator (AS) undertook the remaining 10%. When stored
cervical length measurements were examined by both observers,
the technique of cervical length assessment was reproducible
(n = 30). In 95% of cases, the differences between two measure-
ments by the same observer (MC) was #2.0 mm and between
both investigators (MC and AS), it was #4.0 mm.
Sample Preparation and Longitudinal Cytokine Analysis
At each visit, a single Dacron swab was obtained from the
posterior vaginal fornix in order to obtain a high vaginal sample
(referred to as a cervico-vaginal fluid, CVF). At the time of
speculum examination, the swab was placed in the posterior
vaginal fornix for 10 seconds to achieve saturation, then
transferred into 750 ml of standard phosphate-buffered saline
solution containing protease inhibitor [1 protease inhibitor cocktail
tablet (Complete, Roche Diagnostics GmbH, Germany) dissolved
in 50 ml standard phosphate-buffered saline solution (Sigma-
Table 1. Percentages of cervico-vaginal fluid samples with
cytokine concentrations above the limit of detection for each
biomarker for cases and controls between 16 and 24 weeks of
gestation.
Cytokine
Detectable
Concentrations %
IL-1b Controls 100
Cases 100
IL-4 Controls 59–78
Cases 61–100
IL-6 Controls 71–94
Cases 89–100
IL-7 Controls 33–58
Cases 25–78
IL-8 Controls 100
Cases 100
G-CSF Controls 88–100
Cases 100
GM-CSF Controls 31–50
Cases 39–75
IFN-c Controls 53–83
Cases 72–85
MCP-1 Controls 53–78
Cases 77–100
MIP-1b Controls 88–97
Cases 94–100
TNF-a Controls 77–100
Cases 89–100
Samples with values below the limit of detection were included in all data
analysis using interval regression (see methods). Interleukin (IL)-1b, IL-4, IL-6, IL-
7, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage
colony-stimulating factor (GM-CSF), interferon (IFN)-c, monocyte chemotactic
protein (MCP)-1, macrophage inflammatory protein (MIP)-1b, tumour necrosis
factor (TNF)-a.
doi:10.1371/journal.pone.0052412.t001
Cytokines and a Short Cervix in Preterm Birth
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Aldrich Company, Ayrshire, UK)], and immediately transported
on ice to the laboratory. The swab was then removed, placed in a
clean tube, vortexed for 10 seconds and centrifuged (2600 g for 10
minutes, 4uC). Resultant fluid was collected and added to the fluid
in the original tube. This was mixed and centrifuged for a further
10 minutes to remove cell debris. Cell-free supernatants were
divided into aliquots (110 ml) and stored at 280uC until analysis.
Longitudinal inflammatory marker analysis was undertaken on
477 individual samples from 78 women. The women included for
analysis from the control group were chosen based on them having
at least 4 longitudinal samples taken over the second trimester
Figure 1. Enrolment, randomization and follow-up of participants in the study.
doi:10.1371/journal.pone.0052412.g001
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available for analysis. A minimum of six samples were analyzed for
women who developed a short cervix (cases). The samples from
cases included pre and post intervention samples and the sample
obtained at the visit when the cervix was found to be short prior to
being randomised to an intervention. Samples were thawed at
room temperature, briefly vortexed and analyzed by 11-plex fluid-
phase immunoassay for interleukin (IL)-1b, IL-4, IL-6, IL-7,
granulocyte colony-stimulating factor (G-CSF), granulocyte-mac-
rophage colony-stimulating factor (GM-CSF), interferon (IFN)-c,
monocyte chemotactic protein (MCP)-1, macrophage inflamma-
tory protein (MIP)-1b and tumour necrosis factor (TNF)-a (Bio-
Rad Laboratories, Hemel Hempstead, Hertsfordshire, UK) in
duplicate according to manufacturer’s instructions on a Luminex-
100 cytometer (Luminex Corporation, Austin, Texas) equipped
with StartStation software (Version 2.0; Applied Cytometry
Systems, Dinnington, UK). The choice of analytes reflected those
recognized to be representative of inflammatory processes in the
published literature [29] and by the investigators. A pooled control
sample achieved by combining a random set of 40 samples was
included in individual plates to control for inter-plate variation.
Concentrations in pg/ml were calculated from the standard
curves using 4 parameter logistic regression with Bio-Plex software
(Bio-Rad Laboratories, Hemel Hempstead, Hertsfordshire, UK).
The lower limits of detection was 0.8 pg/ml for IL-1b, 0.5 pg/ml
for IL-4, 1.1 pg/ml for IL-6, 0.5 pg/ml for IL-7, 1.1 pg/ml for G-
CSF, 4.5 pg/ml for GM-CSF, 19.3 pg/ml for IFN-c, 6.7 pg/ml
for MCP-1, 1.1 pg/ml for MIP-1b and 3.0 pg/ml for TNF-a.
Figure 2. Kaplan-Meier plot to compare time to delivery following allocation to treatment with progesterone (solid line, n=17) and
cervical cerclage (dashed line, n=19); p =0.23. Vaginal progesterone was prescribed on the day of allocation; women with cerclage received
treatment within 2.5 (SD 3.9) days.
doi:10.1371/journal.pone.0052412.g002
Table 2. Baseline maternal characteristics of women who had inflammatory marker analysis.
Controls (n=42) Cases (n =36) Difference (CI)
Maternal age (y) 30.5 (5.9) 29.8 (6.6) 0.7 (22.1 to 3.5)
Height (m) 1.6 (0.12) 1.6 (0.12) 0.0 (20.05 to 0.05)
Weight (kg) 76.0 (13.5) 76.3 (17.6) 20.30 (27.5 to 6.9)
Body mass index at booking (kg/m2) 27.3 (6.0) 26.6 (6.2) 0.7 (22.1 to 3.5)
Risk factors
Previous preterm birth (24–34 weeks) Previous
preterm pre-labour rupture of membranes
Previous 2nd trimester loss (16–24 weeks)
23 (55%)
23 (55%)
20 (48%)
11 (31%)
18 (50%)
27 (75%)
24 (3 to 45)
5 (217 to.27)
2 (29 to 12)
Current smoker 3 (7%) 2 (6%) –
Ethnic group*
White
Black
Other
14 (33%)
25 (60%)
3 (7%)
4 (11%)
30 (83%)
2 (6%)
Reference
24 (6 to 43)
16 (226 to 58)
Positive for bacterial vaginosis if tested 6/18 (33%) 10/31 (32%) 1 (226 to 28)
Data are mean (standard deviation) or n (%).
*Ethnic group was self-reported.
doi:10.1371/journal.pone.0052412.t002
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Statistical Analysis
The sample size was not pre-determined due to inadequate
published data informing the gestational profile of cervico-vaginal
inflammatory markers, or of any relationship with repeated
measures of cervical length. This study and analysis was therefore
exploratory in nature. The predefined endpoints were cytokine
concentrations prior to cervical shortening, and before and after
treatment. Cytokine levels were expressed as pg/ml. The study
was not designed or powered to directly compare the two
treatment groups (e.g. for cytokine concentrations, cervical length
or preterm birth), although some exploratory comparisons have
been included. The data were analyzed using Stata (version 10.1,
Stata Corp, College Station, Texas). Distributions of data were
first established by examination of distributional plots for raw and
transformed values. Log transformations were used for all
biomarkers to achieve approximate normality. Estimates and tests
of differences, both between and within subjects, used linear
regression adjusting for repeated measures and non-normality
through the use of generalized estimating equations. Where
sample concentrations were below the limit of detection for the
assay, an interval regression method was used, with the missing
values taken as being at an unknown point on the interval between
zero and the smallest positive concentration observed. The percent
of samples with concentrations above the detectable range is
shown in Table 1.
In order to determine the difference in cytokine expression in
cases and controls prior to treatment, samples up to and including
the visit at which the cervix shortened but prior to treatment over
a period of time from 16 to 24 weeks’ were included and the
average difference between cases and controls determined using a
correction for effect of gestation (2-weekly categories) and inter-
assay plate variation. Results were expressed as ratios of the
cytokines concentrations in cases and controls with 95% confi-
dence intervals. A p value of less than 0.05 was considered to
indicate statistical significance. Actual p-values are given (usually
to 2 decimal places), except for very small values, shown as
p,0.001.
Figure 3. Representative gestational profile of 11 cytokines measured longitudinally in cervico-vaginal fluid samples from a
pregnant woman at risk of spontaneous preterm labour who did not demonstrate cervical shortening or deliver preterm. A.
Interleukin (IL)-4 (solid line, closed circle); IL-7 (dotted line, open triangle); granulocyte-macrophage colony-stimulating factor (GM-CSF) (dashed line,
closed square). B. IL-1b (solid line, closed circle); interferon (IFN)-c (dotted line, open triangle); macrophage inflammatory protein (MIP)-1b (dashed
line, closed square). C. IL-8 (solid line, closed circle); IL-6 (dotted line, open triangle) circle); granulocyte colony-stimulating factor (G-CSF) (dashed line,
closed square). D. Monocyte chemotactic protein (MCP)-1 (solid line, closed circle) and tumour necrosis factor (TNF)-a (dotted line, open triangle).
doi:10.1371/journal.pone.0052412.g003
Cytokines and a Short Cervix in Preterm Birth
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Results
A total of 1223 women were assessed for eligibility and 112
women were enrolled into this observational study (Figure 1). The
final study group (women who provided suitable samples for
longitudinal analysis of CVF cytokines) were n= 42 controls and
n=36 cases. Table 2 summarizes the baseline characteristics of the
cohort providing longitudinal samples for cytokine analysis
(n = 78). Women in the control group had numerically more
previous preterm deliveries between 24 and 34 weeks’ gestation
and were more likely to be White compared to women destined to
develop a short cervix (,25 mm at ,24 weeks’ gestation), who
reported more previous second trimester losses and were more
likely to be Black. The percentage of women with bacterial
vaginosis in each group was similar (Table 2). Mean gestational
age at birth in the control women was 37.9 (SD 3.49) weeks. There
was no statistical difference in gestational age at birth between
treatment groups (p = 0.23), with a mean gestational age at birth in
the cerclage group of 33.7 (SD 7.7) weeks and 31.5 (SD 9.0) weeks
in the progesterone group (Figure 2).
The multiplex immunoassays detected all the different inflam-
matory cytokines in the panel. Representative cytokine gestational
profiles from 3 women are shown: a control (Figure 3), a case who
received a cervical cerclage following cervical shortening (Figure 4)
and a case who received vaginal progesterone following cervical
shortening (Figure 5).
Overall, there was no global rise in all inflammatory markers
prior to cervical shortening. However, GM-CSF and MCP-1 were
raised in cervico-vaginal fluid in samples taken up to (and
including) when the cervix was found to be short but prior to
treatment in women at risk of SPTL (Table 3). These cytokines
were raised across the 16–24 week period; there was no evidence
of a progressive rise with gestation, nor an increase immediately
preceding cervical shortening.
Among the cases, mean estimates of GM-CSF [pg/ml (CI)] at 4
weeks, 2 weeks pre cervical shortening, and at cervical shortening
Figure 4. Representative gestational profile of 11 cytokines measured longitudinally in cervico-vaginal fluid samples from a
representative woman at risk of spontaneous preterm labor who demonstrated cervical shortening and randomised to receive a
cervical cerclage at 21+4 weeks’ gestation and delivered preterm at 32 weeks’ gestation. A. Interleukin (IL)-4 (solid line, closed circle); IL-7
(dotted line, open triangle); granulocyte-macrophage colony-stimulating factor (GM-CSF) (dashed line, closed square). B. IL-1b (solid line, closed
circle); interferon (IFN)-c (dotted line, open triangle); macrophage inflammatory protein (MIP)-1b (dashed line, closed square). C. IL-8 (solid line, closed
circle); IL-6 (dotted line, open triangle) circle); granulocyte colony-stimulating factor (G-CSF) (dashed line, closed square). D. Monocyte chemotactic
protein (MCP)-1 (solid line, closed circle) and tumour necrosis factor (TNF)-a (dotted line, open triangle).
doi:10.1371/journal.pone.0052412.g004
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(approximately 20 weeks on average) were 0.0015 (0.000013 to
0.18); 0.27 (0.022 to 3.3) and 0.13 (0.019 to 0.82), respectively.
Corresponding values in the controls at 16, 18, 20 weeks were
0.019 (CI 0.0015 to 0.23), 0.0095 (0.0012 to 0.075), 0.0064
(0.0013 to 0.032). There was a substantial change apparent in the
GM-CSF group prior to cervical shortening that did not match
any change with gestation in the controls. The same pattern was
found for MCP-1 [pg/ml (CI)]; corresponding values were 1.2 pg/
ml (0.065 to 23), 5.6 (0.91 to 34) and 4.9 (1.3 to 19) for the cases;
and 1.2 (0.17 to 8.8), 0.99 (0.21 to 4.6) and 0.65 (0.20 to 2.1) for
the controls. Overall mean estimates of GM-CSF concentrations
were relatively low as 82 (34%) of the 238 GM-CSF values
measured up to the point of cervical shortening prior to treatment
were below the lower limit of detection. These values were treated,
using interval regression, as being at an unknown point in the
range 0 to 0.1. GM-CSF was more often above the limit of
detection in case samples than controls (Table 2). As a sensitivity
analysis, a logistic regression was carried out, comparing samples
with undetectable and detectable levels of GM-CSF, using the
same samples as in Table 3. The odds ratio was 8.8 (1.6 to 49),
p = 0.012; confirming that detectable levels of GM-CSF are linked
to cervical shortening.
Vaginal progesterone treatment following cervical shortening
did not significantly reduce any cytokine concentration (Table 4).
Indeed, IL-1b, IL-4 and MIP-1b concentrations were higher post
treatment. The insertion of a cervical cerclage was also associated
with higher cervico-vaginal fluid concentrations of IL-6, IL-8, G-
CSF, IFN-c and TNF-a compared with pre-treatment values.
Cerclage-associated increases in IL-1b, IL-6, G-CSF and IFN-c
were significantly greater than in the progesterone group [weekly
increase of IL-1b and IL-7 concentration 15% (p= 0.02) and 63%
(p= 0.02), respectively].
Cervical length at recruitment was similar in women who later
received cerclage or progesterone (Figure 6A). The mean (SD)
gestation at which cervical shortening was detected was 18.7 (2.5)
weeks in the cerclage group [cervical length was 17.5 (6.6) mm]
Figure 5. Gestational profiles of 11 cytokines measured longitudinally in cervico-vaginal fluid samples from a representative
woman at risk of spontaneous preterm labor who demonstrated cervical shortening, was allocated to receive vaginal progesterone
after the 23+1 weeks’ gestation CVF sample was taken, and who delivered preterm at 30+1 weeks’ gestation. A. Interleukin (IL)-4 (solid
line, closed circle); IL-7 (dotted line, open triangle); granulocyte-macrophage colony-stimulating factor (GM-CSF) (dashed line, closed square). B. IL-1b
(solid line, closed circle); interferon (IFN)-c (dotted line, open triangle); macrophage inflammatory protein (MIP)-1b (dashed line, closed square). C. IL-8
(solid line, closed circle); IL-6 (dotted line, open triangle) circle); granulocyte colony-stimulating factor (G-CSF) (dashed line, closed square). D.
Monocyte chemotactic protein (MCP)-1 (solid line, closed circle) and tumour necrosis factor (TNF)-a (dotted line, open triangle).
doi:10.1371/journal.pone.0052412.g005
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and 19.7 (2.8) weeks for the progesterone group [cervical length
17.0 (4.7)]. Figure 6B shows cervical length by time before and
after cervical shortening by treatment group and by gestational
age for controls who did not experience cervical shortening. As
there was a chance difference in cervical length measured 2 weeks
prior to shortening between the two groups, this was adjusted for
in the analysis. Following cerclage, cervical length increased [mean
increase 11.5 mm two weeks’ post-treatment (95% CI 5.9 to 17.1;
p,0.001); Figure 6B]. Following progesterone treatment, cervical
length did not alter significantly (Figure 6B). The mean (CI)
cervical length of women in the cerclage group was 14.66 (8.42 to
20.88) mm longer than that of the progesterone group at 2 weeks
post treatment (Figure 6B).
Discussion
This study provides comprehensive longitudinal cervico-vaginal
cytokine profiles of high-risk women from 16 weeks of pregnancy
together with cervical length measurement before and after
treatment with cervical cerclage and vaginal progesterone. The
working hypothesis was based on the proposed causal relationship
between inflammation and a sonographic short cervix [14].
Despite the large body of evidence to suggest that a global rise
Table 3. Inflammation as a marker for cervical shortening.
Cytokine Geometric Means (IU/L, 95% Confidence Interval) Ratio (95% CI) p value
Control group (# 24 weeks’)
Short cervix group (prior to
cervical shortening)
IL-1b 108 (63.8 to 183) 112 (63.4 to 200) 1.04 (0.49–2.22) 0.91
IL-4 0.139 (0.049 to 0.391) 0.138 (0.048 to 0.392) 0.992 (0.245 to 4.01) 0.99
IL-6 3.37 (1.45 to 7.84) 4.88 (1.95 to 12.3) 1.45 (0.448 to 4.69) 0.54
IL-7 0.00850 (0.00237 to 0.0305) 0.0248 (0.006 to 0.101) 2.91 (0.546 to 15.6) 0.21
IL-8 528 (356 to 782) 547 (354 to 844) 1.036 (0.595 to 1.80) 0.9
G-CSF 84.3 (42.5 to 167) 77.8 (37.4 to 162) 0.92 (0.357 to 2.39) 0.87
GM-CSF 0.00423 (0.00084 to.0214) 0.068 (0.0108 to 0.435) 16.2 (1.78 to 147) 0.013
IFN-c 4.63 (1.16 to 18.4) 5.19 (1.09 to 24.7) 1.12 (0.156 to 8.09) 0.91
MCP-1 0.871 (0.279 to 2.72) 4.21 (1.21 to 14.6) 4.83 (1.02 to 23.0) 0.048
MIP-1b 28.4 (18.1 to 44.7) 55.1 (31.2 to 97.0) 1.94 (0.961 to 3.91) 0.065
TNF-a 8.29 (4.35 to 15.8) 7.75 (3.69 to 16.3) 0.93 (0.364 to 2.40) 0.88
Comparison of eleven cervico-vaginal fluid cytokine concentrations up to 24 weeks of gestation in controls (women with cervical measurements $25 mm, n = 42) and
cases (women who develop a short cervix, including data up until the day a short cervix was detected, but prior to receiving randomised treatment; n = 36). Ratios of
geometric means are shown.
Estimates are adjusted for systematic changes with gestation and (using a pooled assay) for differences between individual assay plates. A random effects estimator is
used to allow for multiple measurements per woman.
Interleukin (IL)-1b, IL-4, IL-6, IL-7, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-c,
monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1b, tumour necrosis factor (TNF)-a.
doi:10.1371/journal.pone.0052412.t003
Table 4. Comparison of cervico-vaginal (CVF) cytokine concentrations before and after treatment with cervical cerclage and
vaginal progesterone.
Inflammatory Marker
Cerclage Ratio (95% Confidence
Interval; p value)
Progesterone Ratio (95%
Confidence Interval; p value)
Cerclage versus Progesterone Ratio
(95% Confidence Interval; p value)
IL-1b 3.1 (2.0–4.7; ,0.001) 1.6 (1.0–2.5; 0.04) 1.9 (1.1–3.4; 0.02)
IL-4 2.8 (1.2–6.3; 0.02) 2.5 (1.0–6.2; 0.04) 1.1 (0.4–3.4; 0.88)
IL-6 5.8 (2.3–14.5; ,0.001) 1.2 (0.5–3.2; 0.68) 4.7 (1.4–16.4; 0.01)
IL-7 1.7 (0.4–7.0; 0.49) 0.9 (0.2–4.4; 0.92) 1.8 (0.3–12.9; 0.56)
Il-8 1.9 (1.2–3.2; 0.01) 1.6 (0.9–2.7; 0.10) 1.2 (0.6–2.5; 0.54)
G-CSF 3.5 (1.7–7.4; 0.001) 0.8 (0.4–1.8; 0.56) 4.4 (1.6–12.3; 0.004)
GM-CSF 1.2 (0.2–6.2; 0.82) 0.3 (0.1–2.1; 0.24) 3.6 (0.4–34.9; 0.27)
IFN-c 10.4 (3.0–35.9;,0.001) 1.2 (0.3–4.4; 0.80) 8.8 (1.7–47.2; 0.01)
MCP-1 1.7 (0.5–5.9; 0.44) 2.1 (0.5–8.1; 0.28) 0.8 (0.1–4.4; 0.78)
MIP-1b 2.1 (1.3–3.4; 0.001) 1.8 (1.1–2.9; 0.02) 1.2 (0.6–2.2; 0.59)
TNF-a 3.7 (2.1–6.7; ,0.001) 1.7 (0.9–3.2; 0.08) 2.2 (1.0–4.7; 0.06)
Interleukin (IL)-1b, IL-4, IL-6, IL-7, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-c,
monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1b, tumour necrosis factor (TNF)-a.
doi:10.1371/journal.pone.0052412.t004
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in cytokines is central to the initiation of inflammation-induced
spontaneous preterm labour [15–16], we only detected increased
concentrations of 2 ‘early inflammatory response’ cytokines, GM-
CSF and MCP-1, in cervico-vaginal fluid of women destined to
develop a short cervix compared to controls.
Figure 6. Comparison of cervical length, measured by transvaginal ultrasound in vivo, in controls and in women with a short cervix
who were treated with a cervical cerclage or progesterone when the cervix shortened to # 25 mm. A. Cervical length measurements
versus the gestation at which measurements were obtained (controls, solid line, closed circles; cerclage group, dashed line, closed triangle and
vaginal progesterone, dashed line, closed circle). B. Cervical length measurements versus the time from when cervical shortening was first detected
(cerclage group, dashed line, closed triangle and vaginal progesterone, dashed line, closed circle). Cervical length measurements for controls are
shown against gestational age (solid line, closed circles).
doi:10.1371/journal.pone.0052412.g006
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GM-CSF is a growth factor for haematopoietic progenitor cells
and differentiation factor for granulocytic and monocytic cell
lineages, capable of phagocytosis, antigen presentation, cytokine
production and extracellular matrix remodelling [30]. Concentra-
tions of GM-CSF are known to decrease from early- to mid-
pregnancy in maternal plasma in women who have term deliveries
[24], but the role of this cervico-vaginal cytokine in women at risk
of spontaneous preterm labour has not been previously described.
MCP-1 is a soluble chemotactic factor capable of attracting
macrophages, T lymphocytes and dendritic cells to sites of tissue
injury, and has been implicated in the premature activation of a
cascade of inflammatory events leading to preterm delivery [31].
Cytokine analysis from umbilical cord blood taken at delivery also
indicates the strong correlation between increased levels of MCP-1
and preterm delivery [32]. Our study indicates that both MCP-1
and GM-CSF cytokines may be involved in the pathophysiological
process of cervical shortening early in pregnancy although
concentrations in both cytokines were relatively low even in the
case group. The higher concentrations of traditionally measured
cytokines, IL-6, IL-1b and IL-8, in all women (including controls)
suggest these cytokines play a minimal role in cervical shortening.
The ethnic disparity between previous history and short cervices in
our cases and controls reflects established host genotype-environ-
ment risk factors [33–34].
In the United Kingdom, progesterone is still not routinely
administered to all women with a previous preterm delivery, but in
2011 the US Food and Drug Administration approved the use of
intramuscular 17-hydroxyprogesterone caproate for prevention of
preterm birth in women at risk [35]. More recently, vaginal
progesterone was shown to reduce SPTL before 28, 33 and 35
weeks of gestation with improved neonatal outcome in women
with a sonographic short cervix [36,37]. However, the mechanism
of action for progesterone in preventing SPTL has not been clearly
elucidated. Progestational agents have been proposed to inhibit
cervical ripening through inhibition of inflammatory pathways
[38], thus modifying the host immune response. This hypothesis
derived from animal studies [39] suggests that progesterone may
prevent spontaneous preterm labour in susceptible individuals
[33]. The data presented here do not demonstrate a beneficial
effect of vaginal progesterone treatment on commonly measured
cervico-vaginal markers of inflammation or cervical length
suggesting that if this steroid does prevent early delivery, it must
be acting via another mechanism. Cerclage, on the other hand,
appears to cause a localized inflammatory response possibly
secondary to trauma, which did not acutely induce further cervical
shortening; an observation that provides evidence against the
hypothesis that inflammation drives cervical shortening. The mean
gestational age at delivery in women with a previous preterm birth
who did not develop a short cervix was 37.9 weeks. This
observation may allow clinicians to question the value of
administering progesterone based on a woman’s history alone.
A strength of our study was the use of multiplex immunoassays,
which allowed the measurement of several cytokines simulta-
neously in small volumes of cervico-vaginal fluid and thus
enhanced our ability to understand the complex integrated
networks in which cytokines operate [29]. Use of cervico-vaginal
fluid samples also enabled us to study the local inflammatory
milieu without the contribution of systemic effects on cytokine
concentration which may have been secondary to other factors. A
potential weakness of the study was the limited number of women
who delivered preterm, although this was not our study endpoint.
Whilst we could identify two biomarkers as potential predictors of
a short cervix, the impact of cytokines on the preterm delivery rate
could not be ascertained. Sample collection deliberately ceased at
28 weeks of gestation (when women were discharged from the
preterm surveillance clinic), which precluded determination of the
cervico-vaginal cytokine profiles immediately preceding labour.
Given the large inter-woman variability observed, the longitudinal
design allowed robust assessment of temporal changes in cytokine
concentrations in each individual. Ideally, an understanding of the
genetic host contribution to cytokine interaction, although outside
the scope of this study, would enable further insight into the
pathophysiological processes at play. Other limitations that should
be considered when interpreting the findings of this study are that
we did not compare cytokine profiles in high risk controls to those
of a low-risk group of women recruited in parallel and that
bacterial vaginosis was not routinely screened for in all recruits.
Our analysis of inflammatory markers and mediators in high-
risk women provides insight into the mechanisms involved in
cervical shortening and the maternal inflammatory cascade. We
have highlighted that progesterone, administered vaginally at a
daily dose of 400 mg, does not suppress local inflammatory events.
This knowledge may not only allow a deeper insight into
pathophysiology, but it may also facilitate a tailored approach to
individualized healthcare, where intervention may be more
appropriately targeted at those who are likely to benefit. The
potential relation between GM-CSF and MCP-1 and cervical
shortening will need to be validated in a larger cohort of both high
and low-risk women. The relative benefit of progesterone and
cerclage treatment for women at high risk of spontaneous preterm
labor could be further explored in a future randomised clinical
trial.
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